Recurrent abortion and moderate or strong antiphospholipid antibody production

Ogasawara, Mayumi; Sasa, H.; Katano, Kinue; Aoyama, Tomomi; Aoki, Koji; Suzumori, Kaoru

doi:10.1016/s0020-7292(98)00099-x

Cited by 14 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these 46, 26 were aPE-positive, and of the 21 who produced IgG aPE, only one had a successful next pregnancy. A successive report from this institution assayed for aPE by ELISA, but did not differentiate aPE-positive patients from other aPL-positive patients [41].…”

Section: Ape and Clinical Pathology Associationsmentioning

confidence: 91%

Anti-phosphatidylethanolamine (aPE) Antibodies: a Survey

McIntyre

Wagenknecht

2000

Journal of Autoimmunity

View full text Add to dashboard Cite

Section: Ape and Clinical Pathology Associationsmentioning

confidence: 91%

Anti-phosphatidylethanolamine (aPE) Antibodies: a Survey

McIntyre

Wagenknecht

2000

Journal of Autoimmunity

View full text Add to dashboard Cite

“…Medication with low-dose aspirin (40 mg/ day) had been started from 10 weeks of gestation in the previous study [9].…”

Section: Case Reportmentioning

confidence: 99%

Use of Aspirin and Low-Molecular-Weight Heparin to Prevent Recurrence of Maternal Floor Infarction in Women without Evidence of Antiphospholipid Antibody Syndrome

Makino

Suzuki²,

Yamamoto³

et al. 2004

Fetal Diagn Ther

View full text Add to dashboard Cite

During pregnancy, maternal floor infarction (MFI) and massive perivillous fibrin deposition (MFD) often cause fetal growth restriction and death, both being markedly increased by occlusion of the maternal intravenous circulation. Incident rates have been reported to be in the range of 0.09–0.5% and recurrent MFI/MFD might be more frequent in early-onset cases. Thus, prevention measures are necessary for high-risk women who have had MFI/MFD as complications in a previous pregnancy. In this report, the use of oral low-dose aspirin at the early trimester and low-molecular-weight heparin drip infusion from the mid-second trimester was examined for this purpose.

show abstract

“…An investigation of Barbui et al 68 indicated a high incidence of LA (positive in 14% of women with abortions). Ogasawara et al 24 found the prevalence of antibodies to be 5.4% IgG and IgM antibodies and 11.3% for LA. Similar results were reported by Soltesz et al 69 with 14.5% LA and 26.1% IgG antibodies alone and 39.0% IgM antibodies alone, respectively, and both antibodies together in 20.3%.…”

Section: Discussionmentioning

confidence: 98%

“…17 The relationship between APS and pregnancy complications including fetal loss has been reviewed recently. [18][19][20][21][22][23] Ogasawara et al 24 found a failure rate of 19.4% after standard therapy. Tincani et al 25 found a complication rate of more than 20%, although standard therapy was associated with a premature birth rate of up to 18.8%, preeclampsia with 11.6%, and intrauterine growth retardation or restriction (IUGR) of 6%.…”

mentioning

confidence: 99%

Pregnancy Outcome in Women with Antiphospholipid Antibodies: Report on a Retrospective Study

Heilmann¹,

Schorch²,

Hahn³

et al. 2008

Semin Thromb Hemost

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) represents a serious risk factor in pregnancy resulting in several complications, leading to fetal loss and hemostatic complications. In this dedicated report, we describe our experiences in the treatment of pregnancies in patients with APS. The retrospective data from 140 pregnant women were investigated, and the treatment results of 121 patients were recorded. We studied two groups of patients receiving different treatment. The first group (n ¼ 78) received the standard therapy with low-weight-molecular heparin (dalteparin 5000 U or certoparin 3000 U daily) and aspirin (100 mg daily) and in the second group (n ¼ 43) an additional 0.2 g/kg intravenous immunoglobulin (IVIG). Outcomes were 74.3% and 83.7% live births in the first group and in the second group, respectively. The abortion rate was similar in both groups (11.5% vs. 11.6%). The late complication rate was lower in the second group (5.8% vs. 14.1%, p < 0.05) than in the group with standard therapy. Interestingly, we found a trend to higher percentage (> 12%) of natural killer (NK) cells in patients with pregnancy complications (60% vs. 12%, p < 0.05). Our retrospective data shows an improvement of late pregnancy complications by additional use of IVIG. It is possible that IVIG influences higher NK cell activity in patients with previous pregnancy complications.

show abstract

Recurrent abortion and moderate or strong antiphospholipid antibody production

Abstract: The live birth rate in patients strongly positive for aPL is lower than that in patients with moderate aPL production even if treatment is performed during pregnancy. However, ASA is useful to treat cases with moderate aPL so that distinction of the two groups is warranted.

Cited by 14 publications

References 19 publications

Anti-phosphatidylethanolamine (aPE) Antibodies: a Survey

Anti-phosphatidylethanolamine (aPE) Antibodies: a Survey

Use of Aspirin and Low-Molecular-Weight Heparin to Prevent Recurrence of Maternal Floor Infarction in Women without Evidence of Antiphospholipid Antibody Syndrome

Pregnancy Outcome in Women with Antiphospholipid Antibodies: Report on a Retrospective Study

Contact Info

Product

Resources

About